New Diagnostic Imaging Agent Identifies Clear Cell Renal Cancer
Radiolabeled 89Zr-DFO-girentuximab PET/CT can accurately and noninvasively identify clear cell renal carcinoma, with minimal toxicity, say researchers reporting results from the phase 3 ZIRCON trial.
Medscape Medical News
source https://www.medscape.com/viewarticle/988493?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/988493?src=rss
Comments
Post a Comment